Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe?
Linked Content This article is linked to Attia et al paper. To view this article visit https://doi.org/10.1111/apt.14538.
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2018-05, Vol.47 (9), p.1318-1319 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1319 |
|---|---|
| container_issue | 9 |
| container_start_page | 1318 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 47 |
| creator | Papanikolaou, I. S. Papadimitropoulos, V. |
| description | Linked Content
This article is linked to Attia et al paper. To view this article visit https://doi.org/10.1111/apt.14538. |
| doi_str_mv | 10.1111/apt.14580 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2024475143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2023831485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3480-304cd0bc339b36ebdb1f6394a308fb77c2223dfaebbede1f1b2f5c9479d80483</originalsourceid><addsrcrecordid>eNp10LtOwzAUBmALgWgpDLwAisQCQ1rfcmNBFXcJCYYuTJHtnBRXTlLsBNStj8ADwMv1STAUGJDwcjx8-nXOj9A-wUPi30jM2yHhUYo3UJ-wOAopZvEm6mMaZyFNCeuhHedmGOM4wXQb9WgWc56wuI8eLgrdNlYLcxIIC0H7CMFq-VZpK1Rnms6tlu9BoS2odrV8FarV9TQQdaufvTDB0fl4fBxYmOoKauc_wphF4EQJp7toqxTGwd73HKDJ5cXk7Dq8vbu6ORvfhorxFIcMc1VgqRjLJItBFpKUMcu4YDgtZZIoSikrSgFSQgGkJJKWkcp4khUp5ikboKN17Nw2Tx24Nq-0U2CMqMGvn1NM_akR4czTwz901nS29st9KpYywtPIq-O1UrZxzkKZz62uhF3kBOefdee-7vyrbm8PvhM7WUHxK3_69WC0Bi_awOL_pHx8P1lHfgAyxotb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2023831485</pqid></control><display><type>article</type><title>Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe?</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Papanikolaou, I. S. ; Papadimitropoulos, V.</creator><creatorcontrib>Papanikolaou, I. S. ; Papadimitropoulos, V.</creatorcontrib><description>Linked Content
This article is linked to Attia et al paper. To view this article visit https://doi.org/10.1111/apt.14538.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14580</identifier><identifier>PMID: 29644736</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antiviral Agents ; Egypt ; Hepatitis C ; Hepatitis C, Chronic ; Humans ; Interferons</subject><ispartof>Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (9), p.1318-1319</ispartof><rights>2018 John Wiley & Sons Ltd</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3480-304cd0bc339b36ebdb1f6394a308fb77c2223dfaebbede1f1b2f5c9479d80483</cites><orcidid>0000-0002-7368-6168 ; 0000-0001-5103-0005</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.14580$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.14580$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29644736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papanikolaou, I. S.</creatorcontrib><creatorcontrib>Papadimitropoulos, V.</creatorcontrib><title>Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe?</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Linked Content
This article is linked to Attia et al paper. To view this article visit https://doi.org/10.1111/apt.14538.</description><subject>Antiviral Agents</subject><subject>Egypt</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic</subject><subject>Humans</subject><subject>Interferons</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10LtOwzAUBmALgWgpDLwAisQCQ1rfcmNBFXcJCYYuTJHtnBRXTlLsBNStj8ADwMv1STAUGJDwcjx8-nXOj9A-wUPi30jM2yHhUYo3UJ-wOAopZvEm6mMaZyFNCeuhHedmGOM4wXQb9WgWc56wuI8eLgrdNlYLcxIIC0H7CMFq-VZpK1Rnms6tlu9BoS2odrV8FarV9TQQdaufvTDB0fl4fBxYmOoKauc_wphF4EQJp7toqxTGwd73HKDJ5cXk7Dq8vbu6ORvfhorxFIcMc1VgqRjLJItBFpKUMcu4YDgtZZIoSikrSgFSQgGkJJKWkcp4khUp5ikboKN17Nw2Tx24Nq-0U2CMqMGvn1NM_akR4czTwz901nS29st9KpYywtPIq-O1UrZxzkKZz62uhF3kBOefdee-7vyrbm8PvhM7WUHxK3_69WC0Bi_awOL_pHx8P1lHfgAyxotb</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Papanikolaou, I. S.</creator><creator>Papadimitropoulos, V.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7368-6168</orcidid><orcidid>https://orcid.org/0000-0001-5103-0005</orcidid></search><sort><creationdate>201805</creationdate><title>Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe?</title><author>Papanikolaou, I. S. ; Papadimitropoulos, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3480-304cd0bc339b36ebdb1f6394a308fb77c2223dfaebbede1f1b2f5c9479d80483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antiviral Agents</topic><topic>Egypt</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic</topic><topic>Humans</topic><topic>Interferons</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papanikolaou, I. S.</creatorcontrib><creatorcontrib>Papadimitropoulos, V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papanikolaou, I. S.</au><au>Papadimitropoulos, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe?</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2018-05</date><risdate>2018</risdate><volume>47</volume><issue>9</issue><spage>1318</spage><epage>1319</epage><pages>1318-1319</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Linked Content
This article is linked to Attia et al paper. To view this article visit https://doi.org/10.1111/apt.14538.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29644736</pmid><doi>10.1111/apt.14580</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-7368-6168</orcidid><orcidid>https://orcid.org/0000-0001-5103-0005</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (9), p.1318-1319 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2024475143 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antiviral Agents Egypt Hepatitis C Hepatitis C, Chronic Humans Interferons |
| title | Editorial: are the “miraculous” direct‐acting antiviral (DAA) regimens really safe? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A19%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editorial:%20are%20the%20%E2%80%9Cmiraculous%E2%80%9D%20direct%E2%80%90acting%20antiviral%20(DAA)%20regimens%20really%20safe?&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Papanikolaou,%20I.%20S.&rft.date=2018-05&rft.volume=47&rft.issue=9&rft.spage=1318&rft.epage=1319&rft.pages=1318-1319&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14580&rft_dat=%3Cproquest_cross%3E2023831485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2023831485&rft_id=info:pmid/29644736&rfr_iscdi=true |